{"analyses":[{"ciLowerLimit":"0.43","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.67","groupDescription":"Stratified Analysis: The stratification factors were Eastern Cooperative Oncology Group performance status (ECOG PS) at randomization (0 vs. 1); Lactate Dehydrogenase (LDH) at randomization (\\<=upper limit of normal (ULN) vs \\>ULN) via local laboratory test; Presence of liver metastases at enrollment (yes vs. no); Prior receipt of prophylactic cranial irradiation (PCI) (yes vs. no).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"< .0001","paramType":"Hazard Ratio (HR)","paramValue":"0.54","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.64","spread":"1.64","upperLimit":"2.73","value":"2.14"},{"groupId":"OG001","lowerLimit":"4.24","spread":"4.24","upperLimit":"5.75","value":"5.36"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"241"},{"groupId":"OG001","value":"242"}],"units":"Participants"}],"description":"PFS was defined as the time from randomization to the date of first documented PD as determined by the IRF according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or death, whichever occurs first. PD was defined as appearance of a new lesion(s), unequivocal progression in non-target lesion(s) or at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimetres (mm).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received atezolizumab, 1200 mg, Q3W as IV infusion on Day 1 of each 21-day cycle until unacceptable toxicity or PD whichever occurred first.","id":"OG000","title":"Atezolizumab"},{"description":"Participants received atezolizumab, 1200 mg, Q3W, as IV infusion and lurbinectedin, 3.2 mg/m\\^2, Q3W, as IV infusion on Day 1 of each 21-day cycle until unacceptable toxicity or PD whichever occurred first.","id":"OG001","title":"Atezolizumab+ Lurbinectedin"}],"paramType":"MEDIAN","populationDescription":"FAS included all participants randomized into the randomized phase, regardless of whether or not the assigned study treatment was received.","reportingStatus":"POSTED","timeFrame":"Up to 26 months","title":"Randomized Phase: Independent Review Facility (IRF) - Assessed Progression Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"months"}